3.1 Hepatocellular Carcinoma & Liver Transplantation

Hepatocellular Carcinoma & Liver Transplantation

Summary of Lecture by Prof. Sanjaya Satapathy, MD, FAASLD

1. Main Clinical Topics Discussed

• Transplant candidacy selection criteria for hepatocellular carcinoma (HCC)
• Milan Criteria and UCSF Expanded Criteria: definitions, comparisons, and outcomes
• Tumor biology as a driver of transplant eligibility
• Absolute contraindications to transplantation in HCC
• Bridging vs. downstaging therapy
• Common board examination pitfalls in HCC transplant decision-making

2. Key Learning Points, Guidelines, and Recommendations

Milan Criteria (Gold Standard)

• Single lesion ≤5 cm, OR up to 3 lesions each ≤3 cm
• Absolute exclusions: macrovascular invasion (portal/hepatic veins) and extrahepatic spread
• Designed for reproducible, imaging-based pre-transplant decision-making — no pathology required
• Represents the point at which HCC transplant outcomes approximate non-HCC transplant outcomes

UCSF Expanded Criteria

• Single lesion ≤6.5 cm, OR up to 3 lesions each ≤4.5 cm, with total tumor diameter ≤8 cm
• Same biologic exclusions apply: no macrovascular invasion, no extrahepatic disease
• Considered a controlled, outcome-preserving expansion of Milan — not an open-ended relaxation
• Key principle: *"Expanded does not mean anything goes"*

Absolute Contraindications to Transplant in HCC

• Extrahepatic metastatic disease — unconditional exclusion
• Macrovascular invasion (portal or hepatic veins) — reflects aggressive biology and unacceptably high recurrence risk
• Uncontrolled tumor progression despite locoregional therapy (e.g., rising AFP, radiographic progression)

Bridging vs. Downstaging Therapy

• Bridging therapy: Applied to patients already within transplant criteria; goal is to maintain eligibility during waitlist period
• Downstaging therapy: Applied to patients initially beyond criteria; goal is to reduce tumor burden to within criteria and demonstrate favorable biology over time
• *Mnemonic:* Bridging = maintain eligibility; Downstaging = earn eligibility

3. Specific Clinical Data, Statistics, and Study Results Cited

• Milan Criteria outcomes:

- 5-year post-transplant survival: ~70%

- HCC recurrence rate: <15%

• UCSF Criteria outcomes:

- 5-year post-transplant survival: 75–80% (comparable to Milan; no statistically significant difference)

- Recurrence rates similarly preserved

• Minimum acceptable survival threshold: 50% at 5 years, as proposed by Bruix and colleagues — serves as a benchmark for evaluating expanded criteria

• Beyond UCSF: Post-transplant survival drops substantially below 50%, consistent across multiple cohort studies

• Metro Ticket Model:

- Integrates tumor size, tumor number, and AFP level to generate individualized, continuous survival estimates

- Demonstrates that predicted 5-year HCC-specific survival declines progressively as AFP rises and tumor burden increases

- Represents a shift from rigid size cutoffs toward biologic risk stratification

4. Practical Takeaways for Clinicians

• Liver transplantation in HCC serves a dual purpose: treating the malignancy AND curing the underlying cirrhosis — both goals necessitate strict selection criteria
• Small differences in tumor size or number are clinically meaningful and can determine transplant eligibility; precision in imaging interpretation is essential
• AFP trends matter: Rising AFP or failure to respond to locoregional therapy signals unfavorable tumor biology and may exclude an otherwise size-eligible patient
• Stability on imaging does not override size/number thresholds — a common and consequential clinical misconception
• MELD score urgency does not apply in HCC the same way as in liver failure — exception points exist because cancer risk, not hepat